Text size
A health worker (C) is preparing a dose of Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic set up in the Derby Arena at Pride Park in Derby, England, on March 31, 2021.
Oli Scarff / AFP by Getty Images
The risk of contracting blood clots is about the same
Pfizer
and Coverna-19 vaccines of Modern as in
AstraZeneca
according to a study published Thursday.
Researchers at the University of Oxford, the same university that contributed to the development of the drug company
AstraZeneca
found that rare blood clotting known as cerebral venous thrombosis occurred in four out of one million people who received the vaccines from the drug company.
Pfizer
and biotechnology
Modern.
This compares to five out of a million people after the first dose of the AstraZeneca-Oxford vaccine, they said.
In both cases, the risk of blood clots is much higher in those who contract the Covid-19 virus. TVC appeared in 39 per million patients, the researchers said.
“I came to two important conclusions. First, Covid-19 significantly increases the risk of CVD, adding to the list of blood clotting problems caused by this infection. Second, the risk of Covid-19 is higher than we see with current vaccines, even for those under 30; something that should be taken into account when considering the balances between the risks and benefits of vaccination, ”said Paul Harrison, professor of psychiatry and head of the translational neurobiology group at Oxford University.
The study has major implications, given how regulators have reacted to blood clot issues. In Europe, several countries have limited the use of AstraZeneca vaccine, and the US is now analyzing the pharmaceutical vaccine
Johnson & Johnson,
which is done using a process similar to the AstraZeneca vaccine and also triggered blood clot problems.
Both Pfizer and Moderna vaccines are produced with the mRNA process, using the molecules in the cells that control protein production to teach the immune system to produce antibodies that fight the coronavirus.